Halozyme Therapeutics, Inc. $HALO Shares Acquired by Corient Private Wealth LLC

Corient Private Wealth LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1,554.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,600 shares of the biopharmaceutical company’s stock after purchasing an additional 184,719 shares during the period. Corient Private Wealth LLC’s holdings in Halozyme Therapeutics were worth $13,231,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC boosted its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC lifted its holdings in shares of Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares during the period. Harbour Investments Inc. lifted its holdings in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares during the period. Finally, Wexford Capital LP bought a new position in Halozyme Therapeutics during the third quarter valued at about $70,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HALO. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. UBS Group reiterated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Morgan Stanley reduced their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Finally, Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the transaction, the director directly owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $51,886,572.40. This represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 93,250 shares of company stock worth $6,299,746. 2.50% of the stock is currently owned by insiders.

Halozyme Therapeutics Trading Up 0.9%

NASDAQ:HALO opened at $69.62 on Wednesday. The stock has a fifty day simple moving average of $68.10 and a 200 day simple moving average of $68.69. The firm has a market capitalization of $8.26 billion, a price-to-earnings ratio of 25.04, a price-to-earnings-growth ratio of 0.29 and a beta of 0.88. Halozyme Therapeutics, Inc. has a 1-year low of $51.06 and a 1-year high of $82.22. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. During the same quarter in the previous year, the company earned $1.11 EPS. The business’s revenue for the quarter was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.